Hallucinogens in Drug Discrimination

  • Lisa E. BakerEmail author
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 36)


Hallucinogens comprise a diverse collection of chemicals with multifarious receptor actions in the central nervous system. Preclinical drug screening methods have proven invaluable in the evaluation and characterization of hallucinogen psychopharmacology. Used in concert with structural chemistry and receptor pharmacology methods, preclinical drug discrimination research has informed our current understanding of hallucinogens and the neurochemical receptor mechanisms responsible for their interoceptive stimulus effects. This chapter summarizes the strengths and limitations of drug discrimination as an in vivo drug detection method and offers a brief review of historical and contemporary drug discrimination research with classical hallucinogens.


Hallucinogens Preclinical drug screening Drug discrimination methods Psychopharmacology Behavioral pharmacology 


  1. Appel JB, Callahan PM (1989) Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol 159:41–46CrossRefGoogle Scholar
  2. Appel JB, White FJ, Holohean AM (1982) Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6:529–536CrossRefGoogle Scholar
  3. Appel JB, West WB, Rolandi WG, Alici T, Pechersky K (1999) Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 64:353–358CrossRefGoogle Scholar
  4. Baker LE, Taylor MM (1997) Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 57:737–748CrossRefGoogle Scholar
  5. Baker LE, Broadbent J, Michael EK, Matthews CA, Metosh RB, West WB, Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol 6:263–275CrossRefGoogle Scholar
  6. Béïque JC, Imad M, Mladenovic L, Gingrich JA, Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci 104(23):9870–9875CrossRefGoogle Scholar
  7. Callahan PM, Appel JB (1988) Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. J Pharmacol Exp Ther 246:866–870PubMedGoogle Scholar
  8. Callahan PM, Appel JB (1990) Differentiation between the stimulus effects of LSD and lisuride using a three-choice drug discrimination procedure. Psychopharmacology 100:13–18CrossRefGoogle Scholar
  9. Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB (2015) The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. Psychopharmacology 232: 275–284CrossRefGoogle Scholar
  10. Colpaert FC (1999) Drug discrimination in neurobiology. Pharmacol Biochem Behav 64:337–345CrossRefGoogle Scholar
  11. Colpaert FC, Niemegeers CJ, Janssen PA (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther 221:206–214PubMedPubMedCentralGoogle Scholar
  12. Conn PJ, Sanders-Bush E (1986) Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the 5-HT2 binding site. J Neurosci 6:3669–3675CrossRefGoogle Scholar
  13. Conn PJ, Janowsky A, Sanders-Bush E (1987) Denervation supersensitivity of the 5-HT1C receptors in rat choroid plexus. Brain Res 400:396–398CrossRefGoogle Scholar
  14. Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M (2012) Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 62:2184–2191CrossRefGoogle Scholar
  15. Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–33CrossRefGoogle Scholar
  16. Fiorella D, Rabin RA, Winter JC (1995a) The role of the 5-H2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology 121:347–356CrossRefGoogle Scholar
  17. Fiorella D, Helsley SE, Lorraine DS, Palumbo PA, Rabin RA, Winter JC (1995b) The role of the 5-H2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology 121:364–372CrossRefGoogle Scholar
  18. Glennon RA (1994) Classical hallucinogens: an introductory overview. NIDA Res Monogr 146:4–32PubMedGoogle Scholar
  19. Glennon RA, Young R (1982) Comparison of behavioral properties of di- and tri-methoxyphenylisopropylamines. Pharmacol Biochem Behav 17(4):603–607CrossRefGoogle Scholar
  20. Glennon RA, Young R (2011) Drug discrimination and in vivo structure-activity relationships. In: Glennon R, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies, 1st edn. Wiley, Hoboken, pp 163–181CrossRefGoogle Scholar
  21. Glennon RA, Rosecrans JA, Young R (1982) The use of the drug discrimination paradigm for studying hallucinogenic agents. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical Press, Amsterdam, pp 69–96Google Scholar
  22. Glennon RA, Titeler M, Mckenney JD (1984a) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511CrossRefGoogle Scholar
  23. Glennon RA, Rosecrans JA, Young R (1984b) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–376CrossRefGoogle Scholar
  24. Glennon RA, Yousif M, Patrick G (1988) Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 29:443–449CrossRefGoogle Scholar
  25. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R et al (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 53:439–452CrossRefGoogle Scholar
  26. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93–97CrossRefGoogle Scholar
  27. Goodwin AK, Baker LE (2000) A three-choice drug discrimination procedure dissociates the discriminative stimulus effects of MDMA and d-amphetamine. Exp Clin Psychopharmacol 8(3):415–423CrossRefGoogle Scholar
  28. Goodwin AK, Pynnonen DM, Baker LE (2003) Serotonergic-dopaminergic mediation of MDMA’s discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74:987–995CrossRefGoogle Scholar
  29. Harris RT, Balster RL (1971) An analysis of the function of drugs in the stimulus control of operant behavior. In: Thompson T, Pickens R (eds) Stimulus properties of drugs. Appleton-Century Crofts, New York, pp 111–132CrossRefGoogle Scholar
  30. Hirschhorn I, Winter JC (1971) Mescaline and LSD as discriminative stimuli. Psychopharmacologia 22:64–71CrossRefGoogle Scholar
  31. Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81(4):595–602CrossRefGoogle Scholar
  32. Holtzman SG, Locke KW (1988) Neural mechanisms of drug stimuli: experimental approaches. Psychopharmacology 4:138–153Google Scholar
  33. Killinger BA, Peet MM, Baker LE (2010) Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol Biochem Behav 96(3):260–265CrossRefGoogle Scholar
  34. Koek W, Slangen JL (1982) Effects of reinforcement differences between drug and saline sessions on discriminative stimulus properties of fentanyl. In: Colpaert FC, Slangen (eds) Drug discrimination: applications in CNS pharmacology. Elsevier, Amsterdam, pp 343–354Google Scholar
  35. Koerner J, Appel JB (1982) Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for ‘hallucinogens’. Psychopharmacology 76(2):130–135CrossRefGoogle Scholar
  36. Kueh D, Baker LE (2007) Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Psychopharmacology 189:447–457CrossRefGoogle Scholar
  37. Kuhn DM, White FJ, Appel JB (1978) the discriminative stimulus properties of LSD: mechanism of action. Neuropharmacology 17:257–263CrossRefGoogle Scholar
  38. Lambe EK, Aghajanian GK (2007) Prefrontal cortical network activity: opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation. Neuroscience 145:900–910CrossRefGoogle Scholar
  39. Lambe EK, Goldman-Rakic PS, Aghajanian GK (2000) Serotonin induces EPSCs preferentially in layer V pyramidal neurons of the frontal cortex in the rat. Cereb Cortex 10:974–980CrossRefGoogle Scholar
  40. Lambe EK, Aghajanian GK (2001) The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci 21:9955–9963CrossRefGoogle Scholar
  41. Marona-Lewicka D, Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 87:453–461CrossRefGoogle Scholar
  42. Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (2002) Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology 64(1):93–107CrossRefGoogle Scholar
  43. McMillan DE, Wenger GR (1984) Bias of phencyclidine discrimination by the schedule of reinforcement. J Exp Anal Behav 42:51–66CrossRefGoogle Scholar
  44. McMillan DE, Hardwick WC, Li M (2001) Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules. Behav Pharmacol 12(3):195–208CrossRefGoogle Scholar
  45. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (2011) Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493:76–79CrossRefGoogle Scholar
  46. Nichols DE (1986) Differences between the mechanism of Action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class. Entactogens J Psychoactive Drugs 18(4):305–313CrossRefGoogle Scholar
  47. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181CrossRefGoogle Scholar
  48. Oberlender R, Nichols DE (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacology 95:71–76CrossRefGoogle Scholar
  49. Overton DA (1979) Influence of shaping procedure and schedules on performance in the two-bar drug discrimination task: a methodological report. Psychopharmacology 65:291–298CrossRefGoogle Scholar
  50. Pranzatelli MR (1990) Neonatal, 5,7-DHT lesions up-regulate (3H)mesulergine-labelled spinal 5-HT1C binding sites in the rat. Brain Res Bull 25:151–153CrossRefGoogle Scholar
  51. Schechter MD (1998) MDMA-like stimulus effects of hallucinogens in male fawn-hooded rats. Pharmacol Biochem Behav 59:265–270CrossRefGoogle Scholar
  52. Schechter MD, Rosecrans JA (1972) Lysergic acid diethylamide (LSD) as a discriminative cue: drugs with similar stimulus properties. Psychopharmacologia 26:313–316CrossRefGoogle Scholar
  53. Shannon HE (1981) Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 216:543–551PubMedGoogle Scholar
  54. Silverman PB & Ho BT (1978) Stimulus properties of DOM: commonality with other hallucinogens. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier/North Holland, Amsterdam, pp 189–198Google Scholar
  55. Stolerman IP (1989) Discriminative stimulus effects of nicotine in rats trained under different schedules of reinforcement. Psychopharmacology 97:131–138CrossRefGoogle Scholar
  56. Stolerman IP (1993) Drug discrimination. In: Van Haaren F (ed) Methods in behavioral pharmacology. Elsevier Science, Amsterdam, pp 217–224CrossRefGoogle Scholar
  57. Swedberg MDB, Jarbe TUC (1986) Drug discrimination procedures: differential characteristics of the drug A vs drug B and the drug A vs drug B vs no drug cases. Psychopharmacology 90:341–346CrossRefGoogle Scholar
  58. White FJ, Appel JB (1982) Lysergic acid diethylamide (LSD) and lisuride: Differentiation of their neuropharmacological actions. Science 216:535–537CrossRefGoogle Scholar
  59. White FJ, Simmons MA, West KB, Holohean AM, Appel JB (1980) The effect of serotonin depletion on the discriminability of LSD. Pharmacol Biochem Behav 13:567–574CrossRefGoogle Scholar
  60. Winter JC (1978) Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. J Pharmacol Exp Ther 204:416–423PubMedGoogle Scholar
  61. Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, Rabin RA (1999) Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283–293CrossRefGoogle Scholar
  62. Winter JC, Doat M, Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337–344CrossRefGoogle Scholar
  63. Winter JC, Eckler JR, Rabin RA (2004) Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233–240CrossRefGoogle Scholar
  64. Winter JC, Rice KC, Amorosi DH, Rabin RA (2007) Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 87:472–480CrossRefGoogle Scholar
  65. Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 203:251–263CrossRefGoogle Scholar
  66. Young R (2009) Drug discrimination. In: Buccafusco JJ (ed) Methods of behavior analysis in neuroscience, 2nd edn. Retrieved from
  67. Young R, Rosecrans JA, Glennon RA (1982) Comparative discriminative stimulus effects of 5-methoxy-N, N-dimethoxytryptamine and LSD. Life Sci 30:2057–2062CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of PsychologyWestern Michigan UniversityKalamazooUSA

Personalised recommendations